Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.22T
24h Vol:
$9.44B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  VYGR
Voyager Therapeutics
VYGR
90 / 100
High Value
High Quality
$7.57arrow_drop_up0.93%$0.07

Performance History

Stocklytics logo
Key Stats
Open$7.56
Prev. Close$7.50
EPS2.97
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$407.25M
PE Ratio2.55
LOWHIGH
Day Range7.47
7.70
52 Week Range6.06
14.34
Ratios
P/B Ratio1.94
Revenue$250.00M
Operating M. %60.03%
Earnings$132.33M
Earnings Growth %385.14%
EBITDA Margin %50.58%
ROE %89.61%
EPS2.97

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

90vs 54. Market Avg.

All Score 90 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

VYGRMARKET
Value8339
Quality8040
Ownership2817
Growth7447
Dividends-38
check_circle

Voyager Therapeutics 's Price growth average in the last 3 years of 21.38% is great compared to market average of 5.28%. This indicates VYGR could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$731.33
24H (%)arrow_drop_up0.69%
24H ($)$5.02
MARKET CAP$690.55B
PRICE$491.23
24H (%)arrow_drop_down1.97%
24H ($)-$9.89
MARKET CAP$462.00B
PRICE$149.12
24H (%)arrow_drop_up0.81%
24H ($)$1.20
MARKET CAP$356.43B
PRICE$126.94
24H (%)arrow_drop_up0.92%
24H ($)$1.16
MARKET CAP$318.60B

About Voyager Therapeutics (VYGR)

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Headquarters
Cambridge
Employees
125
Exchange
NASDAQ
add Voyager Therapeutics  to watchlist

Keep an eye on Voyager Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Voyager Therapeutics 's (VYGR) price per share?

The current price per share for Voyager Therapeutics (VYGR) is $7.57. The stock has seen a price change of $0.07 recently, indicating a 0.93% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Voyager Therapeutics (VYGR)?

For Voyager Therapeutics (VYGR), the 52-week high is $14.34, which is 89.43% from the current price. The 52-week low is $6.06, the current price is 24.92% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Voyager Therapeutics (VYGR) a growth stock?

Voyager Therapeutics (VYGR) has shown an average price growth of 19.83% over the past three years. It has received a score of 81 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Voyager Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Voyager Therapeutics (VYGR) stock price performance year to date (YTD)?

As of the latest data, Voyager Therapeutics (VYGR) has a year-to-date price change of -15.8%. Over the past month, the stock has experienced a price change of -18.25%. Over the last three months, the change has been -0.13%. Over the past six months, the figure is 11.32%. Looking at a longer horizon, the five-year price change stands at -63.54%.

help
Is Voyager Therapeutics (VYGR) a profitable company?

Voyager Therapeutics (VYGR) has a net income of $132.33M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 60.03% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $250.01M, although specific revenue growth data is currently not available. The gross profit is $245.57M. Operating income is noted at $122.01M. Furthermore, the EBITDA is $126.46M.

help
What is the market capitalization of Voyager Therapeutics (VYGR)?

Voyager Therapeutics (VYGR) has a market capitalization of $407.25M. The average daily trading volume is 530.21K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.